Specialized interferon action in COVID-19 #MMPMID35217532
Galbraith MD; Kinning KT; Sullivan KD; Araya P; Smith KP; Granrath RE; Shaw JR; Baxter R; Jordan KR; Russell S; Dzieciatkowska M; Reisz JA; Gamboni F; Cendali F; Ghosh T; Guo K; Wilson CC; Santiago ML; Monte AA; Bennett TD; Hansen KC; Hsieh EWY; D'Alessandro A; Espinosa JM
Proc Natl Acad Sci U S A 2022[Mar]; 119 (11): ä PMID35217532show ga
The impacts of interferon (IFN) signaling on COVID-19 pathology are multiple, with both protective and harmful effects being documented. We report here a multiomics investigation of systemic IFN signaling in hospitalized COVID-19 patients, defining the multiomics biosignatures associated with varying levels of 12 different type I, II, and III IFNs. The antiviral transcriptional response in circulating immune cells is strongly associated with a specific subset of IFNs, most prominently IFNA2 and IFNG. In contrast, proteomics signatures indicative of endothelial damage and platelet activation associate with high levels of IFNB1 and IFNA6. Seroconversion and time since hospitalization associate with a significant decrease in a specific subset of IFNs. Additionally, differential IFN subtype production is linked to distinct constellations of circulating myeloid and lymphoid immune cell types. Each IFN has a unique metabolic signature, with IFNG being the most associated with activation of the kynurenine pathway. IFNs also show differential relationships with clinical markers of poor prognosis and disease severity. For example, whereas IFNG has the strongest association with C-reactive protein and other immune markers of poor prognosis, IFNB1 associates with increased neutrophil to lymphocyte ratio, a marker of late severe disease. Altogether, these results reveal specialized IFN action in COVID-19, with potential diagnostic and therapeutic implications.
free
free
free
Proc+Natl+Acad+Sci+U+S+A 2022 ; 119 (11): ä
